Biotech Blog

Drug Patent Expirations in February 2010
*Drugs may be covered by multiple patents

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration

ZAGAM
Mylan
sparfloxacin
4,795,751
Feb 4, 2010

TEVETEN
Abbott
eprosartan mesylate
5,185,351
Feb 9, 2010

MYOVIEW
Ge Healthcare
technetium tc-99m tetrofosmin kit
5,045,302
Feb 9, 2010

TEVETEN HCT
Abbott
eprosartan mesylate; hydrochlorothiazide
5,185,351
Feb 9, 2010

HYZAAR
Merck
hydrochlorothiazide; losartan potassium
5,138,069*PED
Feb 11, 2010

COZAAR
Merck
losartan potassium
5,138,069*PED
Feb 11, 2010

EXUBERA
Pfizer
insulin recombinant human
RE37872
Feb 12, 2010

EXUBERA
Pfizer
insulin recombinant human
RE38385
Feb 12, 2010

MEPRON
Glaxosmithkline
atovaquone
4,981,874*PED
Feb 15, 2010

NITRO-DUR
Key Pharms
nitroglycerin
5,186,938
Feb 16, 2010

SANDIMMUNE
Novartis
cyclosporine
7,511,014
Feb 16, 2010

ALDARA
Graceway
imiquimod
4,689,338*PED
Feb 25, [...]

Are you a leader in the biotechnology industry? Do you have specialized expertise and a strong network?
I am looking for a few new members to join the Journal of Commercial Biotechnology’s editorial board. Board member responsibilities include authoring papers, soliciting papers, and reviewing papers. Please check out the journal’s homepage and sample papers for a [...]

I’m giving a talk at Pittcon on biotechnology training this spring. As many readers know, I have been very active in biotechnology education through my books and the classes I teach. So, I’ve got a strong sense of the supply-side of biotechnology education and training, and the academic side of biotechnology education, but would like [...]

Moira Gunn’s Tech Nation interview of Jeremy Abbate and I on the Scientific American worldView project is now available at IT Conversations. For more details, you can also see our video interview and the worldView website.

I’m honored to have been selected as one of the judges of the 2010 Biotech Humanitarian award. More details are available in a press release and blog post about the award.  The Biotechnology Industry Association created the Award to recognize an everyday hero who has helped to heal, fuel and feed the planet through their work [...]

The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 16, Issue 1

Time for a new business model? (free full-text)
Yali Friedman
Why data exclusivity is the new patent protection
Peter Pitts
Follow-on biologic drug competition – No need for new marketing exclusivities
Michael S [...]

Drug Patent Expirations in January 2010
*Drugs may be covered by multiple patents

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration

XOPENEX
Sepracor
levalbuterol hydrochloride
6,083,993
Jan 5, 2010

XOPENEX HFA
Sepracor
levalbuterol tartrate
5,844,002
Jan 5, 2010

XOPENEX
Sepracor
levalbuterol hydrochloride
5,844,002
Jan 5, 2010

XOPENEX HFA
Sepracor
levalbuterol tartrate
5,760,090
Jan 5, 2010

XOPENEX HFA
Sepracor
levalbuterol tartrate
6,083,993
Jan 5, 2010

XOPENEX
Sepracor
levalbuterol hydrochloride
5,760,090
Jan 5, 2010

MONOPRIL
Bristol Myers Squibb
fosinopril sodium
5,006,344*PED
Jan 10, 2010

MONOPRIL-HCT
Bristol Myers Squibb
fosinopril sodium; hydrochlorothiazide
5,006,344*PED
Jan 10, 2010

CLARINEX
Schering
desloratadine
5,178,878
Jan 12, 2010

REMERON SOLTAB
Organon Usa Inc
mirtazapine
5,178,878
Jan 12, 2010

ORAPRED [...]

This is a guest post from Cliff Cramer, Director of the Healthcare and Pharmaceutical Management Program at Columbia Business School. Do you have a response to Cramer’s post? Post them in the comments section below.

Multi-national pharmaceutical and medical technology companies will increase their investments in emerging markets, notably China and India, to access cost [...]

This is a guest post from BiotechBlog reader Viren Konde. Do you have a response to Viren’s post? If so, you may respond in the comments section below.
The recent editorial on “Intellectual property and biotechnology innovation: To protect or not protect” by Dr Yali Friedman, Managing Editor of the Journal of Commercial Biotechnology was thought [...]

Drug Patent Expirations for December 2009

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration

MIGRANAL
Valeant
dihydroergotamine mesylate
5,169,849
Dec 8, 2009

PHOTOFRIN
Axcan Scandipharm
porfimer sodium
5,145,863
Dec 15, 2009

XENICAL
Hoffmann La Roche
orlistat
4,598,089*PED
Dec 18, 2009

CEDAX
Sciele Pharma Inc
ceftibuten dihydrate
4,812,561
Dec 20, 2009

OXILAN-300
Guerbet
ioxilan
4,954,348
Dec 21, 2009

OXILAN-350
Guerbet
ioxilan
4,954,348
Dec 21, 2009

DEFINITY
Lantheus Medcl
perflutren
6,146,657
Dec 22, 2009

ZANTAC 150
Glaxosmithkline
ranitidine hydrochloride
5,102,665*PED
Dec 23, 2009

VALTREX
Glaxosmithkline
valacyclovir hydrochloride
4,957,924*PED
Dec 23, 2009

ZIAGEN
Glaxosmithkline
abacavir sulfate
5,089,500*PED
Dec 26, 2009

TRIZIVIR
Glaxosmithkline
abacavir sulfate; lamivudine; zidovudine
5,089,500*PED
Dec 26, 2009

EPZICOM
Smithkline Beecham
abacavir sulfate; lamivudine
5,089,500*PED
Dec 26, 2009

CORVERT
Pharmacia And Upjohn
ibutilide [...]